Increasing Comfortability With Adopting Risk-Based Approaches

In part 3 of this video interview series, Ken Getz, executive director and research professor, Tufts Center for the Study of Drug Development, Tufts University School of Medicine and Steve Young, chief science officer, CluePoints discuss what could be holding stakeholders back from adopting risk-based quality management.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Blog

ICH E6(R3), Demystified Part 4: Informed Consent

From Signature to System: Why E6(R3) Raises the Bar For years, informed consent has too often...

Blog

RBQM for the Mid-Market Explained

Mid-market sponsors are expected to meet the same ICH E6(R3) standards as large pharma, often with...

Blog

5 Myths Mid-Market Teams Believe About RBQM and What ICH E6(R3) Actually Requires

Risk-Based Quality Management (RBQM) is no longer a future-state concept. Under ICH E6(R3), it is a...